Targeted therapies in colorectal cancer-an integrative view by PPPM - Wikidata - awgldk - TriplyDB

Targeted therapies in colorectal cancer-an integrative view by PPPM

Targeted therapies in colorectal cancer-an integrative view by PPPM

http://www.wikidata.org/entity/Q36646911

about

Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?Genomically driven precision medicine to improve outcomes in anaplastic thyroid cancer EPMA summit 2014 under the auspices of the presidency of Italy in the EU: professional statements Overexpression of arginine transporter CAT-1 is associated with accumulation of L-arginine and cell growth in human colorectal cancer tissue Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells.Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer.Nanocrystalline cerium dioxide efficacy for gastrointestinal motility: potential for prokinetic treatment and prevention in elderly.EPMA position paper in cancer: current overview and future perspectives.FAT1: a potential target for monoclonal antibody therapy in colon cancer.Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer.Lupane-type triterpenes and their anti-cancer activities against most common malignant tumors: A review.Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies.Novel biotechnology approaches in colorectal cancer diagnosis and therapy.Tumor suppressor genes in familial adenomatous polyposis Bone morphogenetic protein 2 (BMP2) induces growth suppression and enhances chemosensitivity of human colon cancer cells Molecular Characterization of Somatic Alterations in Dukes' B and C Colorectal Cancers by Targeted Sequencing MicroRNA-645 is an oncogenic regulator in colon cancer.Anaplastic thyroid carcinoma: Failure of conventional therapy but hope of targeted therapy.Targeted photodynamic therapy as potential treatment modality for the eradication of colon cancer and colon cancer stem cells.Inhibition of caspases primes colon cancer cells for 5-fluorouracil-induced TNF-α-dependent necroptosis driven by RIP1 kinase and NF-κB.HDAC inhibitors show differential epigenetic regulation and cell survival strategies on p53 mutant colon cancer cells.

P2860

Q26740411-8437A478-2E54-4488-A6E7-ED3869233178 Q26752752-ACC50A71-CEC7-4BA7-8687-CA5CA61C60CC Q26820880-0D5B681F-E5DD-47CF-AC3E-8F49A43FEC1F Q30373738-CBCEDB5A-ACC4-4BBC-96CE-BBA995D0E778 Q31139529-ABF194CC-ED93-4D6B-B320-01121A2EB5D3 Q33677971-9E777D90-0376-45A1-A2E1-7DFB27E1073F Q35213124-BD538556-2F3C-41E3-A4A5-CBEF017655A3 Q35219044-41C66E72-5F36-4199-95DA-8FDFB0DEC760 Q35532215-12A0FA60-1E8E-4013-B751-CF5979875307 Q37061340-817F457B-E6E1-48E0-AD0E-BBBE29878A34 Q37622949-D939D6B1-65BF-4BB6-836F-BEA993618E93 Q37654570-402DAAF4-D79E-447C-8509-963B83B215C4 Q38390840-081B5339-69C9-4A6A-981E-14CE9DC06939 Q39151211-748DF639-C35B-49E1-B737-E7A70F4B4ED7 Q39194701-5022E7A9-EA3D-4A26-AD8A-C5EFE13E1654 Q39318496-0582C2BA-41B4-499C-AD38-FAC136150F13 Q41037621-CEAA7EB6-92C1-4DC7-ADB0-4CA98B4E737F Q41098499-ECBAF1D5-8119-4A3E-AA1E-03F999D208E7 Q47631967-4CEF3159-AD0D-4C1D-A988-9884F046D50B Q49486366-7E8EE88A-A504-441E-B327-3BB549297E71 Q50917552-415393D1-7F04-4663-BE84-EF5F6E3A58C0 Q52707747-F6E8599D-E838-4B25-AC6F-257D275DC8D4

P2860

Targeted therapies in colorectal cancer-an integrative view by PPPM

http://www.wikidata.org/entity/Q36646911

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Targeted therapies in colorectal cancer-an integrative view by PPPM

@ast

Targeted therapies in colorectal cancer-an integrative view by PPPM

@en

type

label

Targeted therapies in colorectal cancer-an integrative view by PPPM

@ast

Targeted therapies in colorectal cancer-an integrative view by PPPM

@en

prefLabel

Targeted therapies in colorectal cancer-an integrative view by PPPM

@ast

Targeted therapies in colorectal cancer-an integrative view by PPPM

@en

P1433

Q36646911-A370E18E-819C-43A9-88A5-E017C4C41BEF

P1476

Q36646911-EEAE6289-84AE-4344-A64F-36C43A39D03A

P2093

Q36646911-04B273BD-CD4C-4846-8322-AB6974356FF4

Q36646911-2CA604A8-63DE-4892-B9A0-338A75C9E670

Q36646911-9D93A38F-F02B-4B47-AA6D-7D1EE99FC0B4

P2860

Q36646911-027E6ADE-71DB-4A21-A381-E0C855CF97BB

Q36646911-02C3BA17-73F7-4553-9A19-E3A7C51D95A3

Q36646911-08298030-2A87-44C0-98B0-55FCC335E34B

Q36646911-084C37D0-5060-4F3F-B378-F409B5AE0D7F

Q36646911-0AE54CD3-396C-4E27-9A78-C1967C7AA782

Q36646911-0C2E568E-30D4-4142-8436-7D1A2F9F3B60

Q36646911-0FC93477-E36C-445A-A90A-EB9A8785EFFF

Q36646911-13F3C265-30CF-41B0-B83A-66E42E0236A9

Q36646911-142251AA-53E6-4AED-A145-11046086E727

Q36646911-156C885D-5BE5-4233-97C4-B07DE9291BDB

P2888

Q36646911-BCB55427-5C7D-44C3-8101-C16ED2775746

P304

Q36646911-9CCC3838-1DBF-4F15-A0C6-4981E03FD285

P31

Q36646911-2D8BBE5E-7D1A-4FE7-A3B7-6C1A70C394BC

P356

Q36646911-95B348A8-44F6-41D3-AD7B-EBE1D28FEAF1

P433

Q36646911-1834F66F-3EC3-43B1-8ECC-882EF438E250

P478

Q36646911-60041F44-D848-4A98-AC4C-94220565EE79

P577

Q36646911-8ACE93F1-9DBD-409B-9FDD-E3EE3F8F3EA2

P5875

Q36646911-94689EE4-D323-4C8C-9C59-FCD03B1F20F6

P6179

Q36646911-218E87EF-F33C-434B-A3B8-92317E0B6AF8

P698

Q36646911-FE001A5E-9456-433F-83D9-82C41B661566

P921

Q36646911-A4D3C547-3C7C-4ABA-8E97-407D7E238A5C

P932

Q36646911-17949F4F-7317-4399-BF90-D7C51AD808E7

P356

P1433

The EPMA journal

P1476

Targeted therapies in colorectal cancer-an integrative view by PPPM

@en

P2093

Brendan Doyle

http://www.w3.org/2001/XMLSchema#string

Maria C M Orr

http://www.w3.org/2001/XMLSchema#string

Suzanne Hagan

http://www.w3.org/2001/XMLSchema#string

P2860

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

Modes of resistance to anti-angiogenic therapy

Melanoma genome sequencing reveals frequent PREX2 mutations

An integrated genomic analysis of human glioblastoma multiforme

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Cetuximab for the treatment of colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

P2888

P304

3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1878-5085-4-3

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235377726

http://www.w3.org/2001/XMLSchema#string

P6179

1038409372

http://www.w3.org/2001/XMLSchema#string

P698

23356214

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3584939

http://www.w3.org/2001/XMLSchema#string